PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy

PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy

Researchers are trying to determine the side effects on the heart from immune checkpoint inhibitor (ICI) treatment in patients with cancer.

Inclusion Criteria:

• First time administration of ICI
• Willing and able to return in 4-6 weeks for follow-up study
• Patients with previous heart conditions included (while this may impact MFR the delta MFR is what we are assessing)

Exclusion Criteria:

• Age < 18 years
• Women who are pregnant, or breast-feeding.
• Unable or unwilling to give consent to undergo PET/CT.